Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined ...

Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested ...

Mettler-Toledo’s capital efficiency, strong moat, and robust free cash flow make it a standout investment. Click here to find ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated for the treatment of hyperphagia in ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is increasingly being shaped not by public institutions, but by ...

Alicia Alford, a recent graduate of the BULLS Life Sciences Academy and Durham Technical Community College, said Accelerate ...

The Russian leader’s summary of the phone call didn’t sound nearly as optimistic as Trump’s when it comes to next steps in ...

Columnists have labeled Trump’s bill the second coming of Reagonomics, promising to slash taxes for the wealthy while leaving ...

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.